Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04207931 · ClinicalTrials.gov registry record · Phase 4
Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study
A Phase 4 study of Central Centrifugal Cicatricial Alopecia (CCCA), sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT04207931 is a Phase 4 study of Central Centrifugal Cicatricial Alopecia (CCCA) that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 250 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04207931, a Phase 4 study of Central Centrifugal Cicatricial Alopecia (CCCA), is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to examine photos of CCCA patients taken before and after treatment to compare treatment outcomes between different treatment groups
Conditions Studied
Interventions
- DRUG Triamcinolone Acetonide
- DRUG Minoxidil
- DRUG Topical steroid class I-II
- DRUG Doxycyline
Study Locations (1)
North Carolina
- Wake Forest Baptist Health Department of Dermatology - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2018-04-30 |
| Est. Completion | 2026-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04207931
The ClinicalTrials.gov registry entry for NCT04207931 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Centrifugal Cicatricial Alopecia (CCCA) appearing as the primary indexed condition, and to 4 interventions - of which Triamcinolone Acetonide is the first listed.
NCT04207931 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04207931 about?
NCT04207931 is a clinical study titled "Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study". The objective of this study is to examine photos of CCCA patients taken before and after treatment to compare treatment outcomes between different treatment groups
What is the current status of trial NCT04207931?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 250 participants. The study started on 2018-04-30. Estimated completion is 2026-08.
What conditions does trial NCT04207931 study?
This clinical trial studies the following conditions: Central Centrifugal Cicatricial Alopecia (CCCA).
What interventions are being tested in trial NCT04207931?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), Minoxidil (DRUG), Topical steroid class I-II (DRUG), Doxycyline (DRUG).
Who is sponsoring clinical trial NCT04207931?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04207931 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.